Nevertheless, a prior study showed that IL-17 could induce accumulation and activation of myeloperoxidase+ TANs by stimulating ESCC cells to secret CXCL2 and CXCL3, and IL-17 could also strengthen the killing capacity of TANs by releasing various cytotoxic molecules, which predicted a favorable prognosis in ESCC patients (105). This evidence concerns the gene CXCL2 and esophageal squamous cell carcinoma.